Post-Marketing Surveillance of Polatuzumab Vedotin: A Disproportionality Analysis of the US FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Muscara, Claudia [1 ]
Allegra, Alessandro [2 ]
Tuccoli, Marco [3 ]
Flaccavento, Alessandra [4 ]
Cutroneo, Paola Maria [1 ]
机构：
[1] Univ Hosp Messina, Sicilian Reg Pharmacovigilance Ctr, Clin Pharmacol Unit, Messina, Italy
[2] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Hematol Unit, Messina, Italy
[3] Univ Hosp Pisa, Unit Adverse Drug React Monitoring, Pisa, Italy
[4] Univ Pisa, Dept Clin & Expt Med Sect Pharmacol & Pharmacovig, Pisa, Italy
来源：
DRUG SAFETY | 2024年 / 47卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
210
引用
收藏
页码：1408 / 1408
页数：1
相关论文
共 50 条
  • [1] Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Michele Fusaroli
    Valentina Isgrò
    Paola Maria Cutroneo
    Carmen Ferrajolo
    Valentina Cirillo
    Francesca Del Bufalo
    Emanuel Raschi
    Elisabetta Poluzzi
    Gianluca Trifirò
    Drug Safety, 2022, 45 : 891 - 908
  • [2] Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Fusaroli, Michele
    Isgro, Valentina
    Cutroneo, Paola Maria
    Ferrajolo, Carmen
    Cirillo, Valentina
    Del Bufalo, Francesca
    Raschi, Emanuel
    Poluzzi, Elisabetta
    Trifiro, Gianluca
    DRUG SAFETY, 2022, 45 (08) : 891 - 908
  • [3] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [4] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [5] Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database
    Qing, Guangwei
    Ye, Shiyi
    Wei, Bo
    Yang, Yuanjian
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [6] A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System
    Xu, Jiayan
    Wang, Ruo
    Shen, Kunwei
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2025, 16
  • [7] Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system
    Cheng, Qian
    Shi, Xuan
    Zhao, Yazheng
    Zou, Shupeng
    Sun, Minghui
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 637 - 648
  • [8] Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Shu, Yamin
    Ding, Yufeng
    Liu, Yanxin
    Wu, Pan
    He, Xucheng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
    Chang, En
    Shi, Yong-Fang
    Liu, Jin-Feng
    Wei, Wei
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (12) : 1545 - 1552
  • [10] Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting system
    Liu, Jin-Feng
    Bai, Ying-Tao
    Leng, Yan-En
    Chang, En
    Wei, Yu-Xun
    Wei, Wei
    EXPERT OPINION ON DRUG SAFETY, 2025,
12345